172 related articles for article (PubMed ID: 12818953)
1. Pharmacokinetics and bioavailability of single-dose intranasal hydromorphone hydrochloride in healthy volunteers.
Coda BA; Rudy AC; Archer SM; Wermeling DP
Anesth Analg; 2003 Jul; 97(1):117-23, table of contents. PubMed ID: 12818953
[TBL] [Abstract][Full Text] [Related]
2. A multiple-dose phase I study of intranasal hydromorphone hydrochloride in healthy volunteers.
Rudy AC; Coda BA; Archer SM; Wermeling DP
Anesth Analg; 2004 Nov; 99(5):1379-1386. PubMed ID: 15502034
[TBL] [Abstract][Full Text] [Related]
3. Effect of fluticasone propionate nasal spray on bioavailability of intranasal hydromorphone hydrochloride in patients with allergic rhinitis.
Davis GA; Rudy AC; Archer SM; Wermeling DP; McNamara PJ
Pharmacotherapy; 2004 Jan; 24(1):26-32. PubMed ID: 14740785
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration of a single dose to American kestrels (Falco sparverius).
Guzman DS; KuKanich B; Drazenovich TL; Olsen GH; Paul-Murphy JR
Am J Vet Res; 2014 Jun; 75(6):527-31. PubMed ID: 24866507
[TBL] [Abstract][Full Text] [Related]
5. Dose proportionality and pharmacokinetics of extended-release (OROS®) hydromorphone: a phase 1, open-label, randomized, crossover study in healthy Taiwanese subjects.
Vandenbossche J; Richards HM; Lu CC; Richarz U
Int J Clin Pharmacol Ther; 2014 Mar; 52(3):217-26. PubMed ID: 24472398
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers.
Wermeling DP; Record KA; Kelly TH; Archer SM; Clinch T; Rudy AC
Anesth Analg; 2006 Aug; 103(2):344-9, table of contents. PubMed ID: 16861415
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology and pharmacokinetics of once-daily hydromorphone hydrochloride extended-release capsules.
Vashi V; Harris S; El-Tahtawy A; Wu D; Cipriano A
J Clin Pharmacol; 2005 May; 45(5):547-54. PubMed ID: 15831778
[TBL] [Abstract][Full Text] [Related]
8. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers.
Drover DR; Angst MS; Valle M; Ramaswamy B; Naidu S; Stanski DR; Verotta D
Anesthesiology; 2002 Oct; 97(4):827-36. PubMed ID: 12357147
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and bioavailability of hydromorphone: effect of various routes of administration.
Chang SF; Moore L; Chien YW
Pharm Res; 1988 Nov; 5(11):718-21. PubMed ID: 2470073
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Abuse Potential of Asalhydromorphone, a Novel Prodrug of Hydromorphone, After Intranasal Administration in Recreational Drug Users.
Guenther S; Mickle TC; Barrett AC; Smith A; Braeckman R; Kelsh D; Vince B
Pain Med; 2020 Mar; 21(3):511-520. PubMed ID: 30986302
[TBL] [Abstract][Full Text] [Related]
11. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the thermal antinociceptive effects and pharmacokinetics of hydromorphone hydrochloride after intramuscular administration to cockatiels (Nymphicus hollandicus).
Houck EL; Guzman DS; Beaufrère H; Knych HK; Paul-Murphy JR
Am J Vet Res; 2018 Aug; 79(8):820-827. PubMed ID: 30058846
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food.
Sathyan G; Xu E; Thipphawong J; Gupta SK
BMC Clin Pharmacol; 2007 Feb; 7():2. PubMed ID: 17270055
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, open-label, exploratory dose-ranging trial of intranasal hydromorphone for managing acute pain from traumatic injury.
Wermeling DP; Clinch T; Rudy AC; Dreitlein D; Suner S; Lacouture PG
J Pain; 2010 Jan; 11(1):24-31. PubMed ID: 19592310
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability and pharmacokinetics of intranasal hydromorphone in patients experiencing vasomotor rhinitis.
Davis GA; Rudy AC; Archer SM; Wermeling DP; McNamara PJ
Clin Drug Investig; 2004; 24(11):633-9. PubMed ID: 17523726
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of hydromorphone hydrochloride after intramuscular and intravenous administration of a single dose to orange-winged Amazon parrots (
Sanchez-Migallon Guzman D; Knych H; Douglas J; Paul-Murphy JR
Am J Vet Res; 2020 Nov; 81(11):894-898. PubMed ID: 33107746
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of hydromorphone after intravenous and intramuscular administration in male rhesus macaques (Macaca mulatta).
Kelly KR; Pypendop BH; Christe KL
J Am Assoc Lab Anim Sci; 2014 Sep; 53(5):512-6. PubMed ID: 25255074
[TBL] [Abstract][Full Text] [Related]
18. Single-dose evaluation of safety, tolerability and pharmacokinetics of newly formulated hydromorphone immediate-release and hydrophilic matrix extended-release tablets in healthy Japanese subjects without co-administration of an opioid antagonist.
Toyama K; Uchida N; Ishizuka H; Sambe T; Kobayashi S
J Clin Pharmacol; 2015 Sep; 55(9):975-84. PubMed ID: 25807927
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone.
Takala A; Kaasalainen V; Seppälä T; Kalso E; Olkkola KT
Acta Anaesthesiol Scand; 1997 Feb; 41(2):309-12. PubMed ID: 9062618
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of hydromorphone hydrochloride after intravenous and intramuscular administration in guinea pigs (
Ambros B; Knych HK; Sadar MJ
Am J Vet Res; 2020 Apr; 81(4):361-366. PubMed ID: 32228262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
